vs
Side-by-side financial comparison of BREAD FINANCIAL HOLDINGS, INC. (BFH) and Organon & Co. (OGN). Click either name above to swap in a different company.
Organon & Co. is the larger business by last-quarter revenue ($1.5B vs $975.0M, roughly 1.5× BREAD FINANCIAL HOLDINGS, INC.). On growth, BREAD FINANCIAL HOLDINGS, INC. posted the faster year-over-year revenue change (5.4% vs -3.5%). Over the past eight quarters, BREAD FINANCIAL HOLDINGS, INC.'s revenue compounded faster (-0.8% CAGR vs -4.7%).
Bread Financial Holdings, Inc. is an American publicly traded provider of private label credit cards, coalition loyalty programs, and direct marketing, derived from the capture and analysis of transaction-rich data.
Organon & Co. is an American pharmaceutical company headquartered in Jersey City, New Jersey. Organon specializes in the following core therapeutic fields: reproductive medicine, contraception, psychiatry, hormone replacement therapy (HRT), and anesthesia. Organon produces all its products outside of the United States but receives a third of its revenue from the United States.
BFH vs OGN — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $975.0M | $1.5B |
| Net Profit | — | $146.0M |
| Gross Margin | — | 53.6% |
| Operating Margin | 4.9% | — |
| Net Margin | — | 10.0% |
| Revenue YoY | 5.4% | -3.5% |
| Net Profit YoY | — | 67.8% |
| EPS (diluted) | $1.21 | $0.55 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $1.5B | ||
| Q4 25 | $975.0M | $1.5B | ||
| Q3 25 | $971.0M | $1.6B | ||
| Q2 25 | $929.0M | $1.6B | ||
| Q1 25 | $970.0M | $1.5B | ||
| Q4 24 | $925.0M | $1.6B | ||
| Q3 24 | $983.0M | $1.6B | ||
| Q2 24 | $939.0M | $1.6B |
| Q1 26 | — | $146.0M | ||
| Q4 25 | — | $-205.0M | ||
| Q3 25 | $188.0M | $160.0M | ||
| Q2 25 | $139.0M | $145.0M | ||
| Q1 25 | $138.0M | $87.0M | ||
| Q4 24 | — | $109.0M | ||
| Q3 24 | $2.0M | $359.0M | ||
| Q2 24 | $133.0M | $195.0M |
| Q1 26 | — | 53.6% | ||
| Q4 25 | — | 49.2% | ||
| Q3 25 | — | 53.5% | ||
| Q2 25 | — | 54.8% | ||
| Q1 25 | — | 55.6% | ||
| Q4 24 | — | 56.3% | ||
| Q3 24 | — | 58.3% | ||
| Q2 24 | — | 58.4% |
| Q1 26 | — | — | ||
| Q4 25 | 4.9% | -9.8% | ||
| Q3 25 | 20.2% | 15.2% | ||
| Q2 25 | 18.7% | 14.4% | ||
| Q1 25 | 20.3% | 6.7% | ||
| Q4 24 | -2.9% | 8.1% | ||
| Q3 24 | 4.1% | 13.1% | ||
| Q2 24 | 19.2% | 14.6% |
| Q1 26 | — | 10.0% | ||
| Q4 25 | — | -13.6% | ||
| Q3 25 | 19.4% | 10.0% | ||
| Q2 25 | 15.0% | 9.1% | ||
| Q1 25 | 14.2% | 5.8% | ||
| Q4 24 | — | 6.8% | ||
| Q3 24 | 0.2% | 22.7% | ||
| Q2 24 | 14.2% | 12.1% |
| Q1 26 | — | $0.55 | ||
| Q4 25 | $1.21 | $-0.78 | ||
| Q3 25 | $3.96 | $0.61 | ||
| Q2 25 | $2.94 | $0.56 | ||
| Q1 25 | $2.78 | $0.33 | ||
| Q4 24 | $0.08 | $0.42 | ||
| Q3 24 | $0.05 | $1.38 | ||
| Q2 24 | $2.66 | $0.75 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $3.6B | — |
| Total DebtLower is stronger | $4.3B | — |
| Stockholders' EquityBook value | $3.3B | — |
| Total Assets | $22.7B | — |
| Debt / EquityLower = less leverage | 1.29× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $3.6B | $574.0M | ||
| Q3 25 | $3.8B | $672.0M | ||
| Q2 25 | $3.8B | $599.0M | ||
| Q1 25 | $4.2B | $547.0M | ||
| Q4 24 | $4.0B | $675.0M | ||
| Q3 24 | $3.5B | $763.0M | ||
| Q2 24 | $4.1B | $704.0M |
| Q1 26 | — | — | ||
| Q4 25 | $4.3B | $8.6B | ||
| Q3 25 | $3.8B | $8.8B | ||
| Q2 25 | $4.2B | $8.9B | ||
| Q1 25 | $5.1B | $9.0B | ||
| Q4 24 | $5.6B | $8.9B | ||
| Q3 24 | $4.6B | $8.7B | ||
| Q2 24 | — | $8.7B |
| Q1 26 | — | — | ||
| Q4 25 | $3.3B | $752.0M | ||
| Q3 25 | $3.3B | $906.0M | ||
| Q2 25 | $3.2B | $733.0M | ||
| Q1 25 | $3.1B | $542.0M | ||
| Q4 24 | $3.1B | $472.0M | ||
| Q3 24 | $3.1B | $493.0M | ||
| Q2 24 | $3.2B | $144.0M |
| Q1 26 | — | — | ||
| Q4 25 | $22.7B | $12.9B | ||
| Q3 25 | $21.7B | $13.6B | ||
| Q2 25 | $21.8B | $13.5B | ||
| Q1 25 | $22.4B | $13.2B | ||
| Q4 24 | $22.9B | $13.1B | ||
| Q3 24 | $21.7B | $12.8B | ||
| Q2 24 | $22.1B | $12.2B |
| Q1 26 | — | — | ||
| Q4 25 | 1.29× | 11.49× | ||
| Q3 25 | 1.14× | 9.74× | ||
| Q2 25 | 1.34× | 12.14× | ||
| Q1 25 | 1.67× | 16.52× | ||
| Q4 24 | 1.82× | 18.81× | ||
| Q3 24 | 1.47× | 17.75× | ||
| Q2 24 | — | 60.11× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $568.0M | — |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $568.0M | $141.0M | ||
| Q3 25 | $605.0M | $264.0M | ||
| Q2 25 | $526.0M | $220.0M | ||
| Q1 25 | $393.0M | $75.0M | ||
| Q4 24 | $479.0M | $390.0M | ||
| Q3 24 | $456.0M | $141.0M | ||
| Q2 24 | $477.0M | $332.0M |
| Q1 26 | — | — | ||
| Q4 25 | — | $96.0M | ||
| Q3 25 | — | $218.0M | ||
| Q2 25 | — | $181.0M | ||
| Q1 25 | — | $43.0M | ||
| Q4 24 | — | $335.0M | ||
| Q3 24 | — | $99.0M | ||
| Q2 24 | — | $300.0M |
| Q1 26 | — | — | ||
| Q4 25 | — | 6.4% | ||
| Q3 25 | — | 13.6% | ||
| Q2 25 | — | 11.4% | ||
| Q1 25 | — | 2.8% | ||
| Q4 24 | — | 21.0% | ||
| Q3 24 | — | 6.3% | ||
| Q2 24 | — | 18.7% |
| Q1 26 | — | — | ||
| Q4 25 | — | 3.0% | ||
| Q3 25 | — | 2.9% | ||
| Q2 25 | — | 2.4% | ||
| Q1 25 | — | 2.1% | ||
| Q4 24 | — | 3.5% | ||
| Q3 24 | — | 2.7% | ||
| Q2 24 | — | 2.0% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 3.22× | 1.65× | ||
| Q2 25 | 3.78× | 1.52× | ||
| Q1 25 | 2.85× | 0.86× | ||
| Q4 24 | — | 3.58× | ||
| Q3 24 | 228.00× | 0.39× | ||
| Q2 24 | 3.59× | 1.70× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BFH
Segment breakdown not available.
OGN
| Established Brands | $880.0M | 60% |
| Women’s Health | $389.0M | 27% |
| Biosimilars | $173.0M | 12% |
